The effects of rosiglitazone on the neonatal rat cardiomyocyte transcriptome: a temporal analysis

Willian Abraham da Silveira, Esteban Vazquez-Hidalgo, Elesha Bartolotta, Ludivine Renaud, Paul Paolini, Gary Hardiman

Research output: Contribution to journalArticle

3 Downloads (Pure)

Abstract

Aim: The objective was to determine via high-throughput RNA sequencing the temporal effects of rosiglitazone (Avandia®) on the neonatal rat ventricular myocyte transcriptome. Materials & methods: Neonatal rat ventricular myocytes (NRVMs) were exposed to rosiglitazone in vitro. Meta analyses utilized temporal comparisons of 0.5 h control versus 0.5 h treatment, 0.5 h treatment versus 24 h treatment and 24 h treatment versus 48 h treatment. Results: Time dependent responses were observed. At 0.5 h, the PI3K-AKT signaling pathway was impacted. At 24 h endoplasmic reticulum activity and protein degradation were altered. At 48 h, oxytocin signaling was perturbed. Conclusion: The effects of rosiglitazone occured early and increased in magnitude over time. A protective molecular response was triggered at 24 h and maintained until 48 h. In parallel, a response that can cause cardiac damage was activated. Our findings suggest that rosiglitazone has deleterious effects.

Original languageEnglish
Pages (from-to)1125-1141
Number of pages17
JournalPharmacogenomics
Volume20
Issue number16
DOIs
Publication statusPublished - 22 Nov 2019

Fingerprint Dive into the research topics of 'The effects of rosiglitazone on the neonatal rat cardiomyocyte transcriptome: a temporal analysis'. Together they form a unique fingerprint.

Cite this